Searched for
NEXAVAR
Natco Pharma's partner MylanInc gets USFDA nod for cancer drugThe company's marketing partner Mylan Inc has received a tentative approval from the United States Food and Drug Administration (USFDA).- Natco Pharma's US partner Mylan files application with USFDANatco Pharma's marketing partner Mylan Inc has filed an application with the US health regulator for generic Sorafenib tablets used mainly ...
- Bayer challenges IPAB’s compulsory licence order to Natco Pharma on cancer drug Nexavar“We introduce the product after years of research and investment, while companies like Natco merely copy and manufacture the product,” said...
- IPAB allows Natco Pharma to sell Nexavar; stock gains'Company will continue to market and sell the drug post verdict. It sold Rs 14 crore worth of Nexavar drug in the past 9 months.'
- Bayer says it will defend its intellectual property rights on cancer drugBayer today said it will continue to defend its IP rights while expressing disappointment at the IPAB decision to reject the firm's plea to...
- Intellectual Property Appellate Board postpones Bayer's compulsory licence appealIPAB has postponed German company Bayer AG's appeal against the grant of a compulsory licence of its patented drug Nexavar to Natco Pharma ...
- US accuses India of WTO rules violation over Nexavar: ReportThe government had defended the move, with Commerce and Industry Minister Anand Sharma stating that India did not violate any WTO norms.
- US threatens to take India to WTO over Nexavar GenericThe US has threatened to drag India to the WTO for issuing the firstever compulsory licence to a domestic company to manufacture generic ve...
- Bayer demands withdrawal of Natco Pharma's compulsory licenceIn March, India allowed Natco Pharma to legally make and sell a low-cost version of cancer drug Nexavar at 3% of the original medicine's pr...
- Cipla breached patent rights by slashing cancer drug price: Bayer PharmaBayer has not given its consent to Cipla to launch its generic Sorafenib & co's decision to cut price "is clear patent infringement," Bayer...
- Bayer challenges Nexavar generic licence orderBayer has filed an appeal against a patents order, which allowed domestic drug maker Natco Pharma to sell a generic version of the German f...
- Pharma industry split over nod to Natco to sell Bayer's cancer drugThe decision to allow Natco Pharma to sell Bayer's patented cancer drug Nexavar has divided the pharmaceutical industry.
- Natco Pharma bags licence to sell Nexavar drug; stock upShares of Natco Pharma extended gains for the second straight day on Tuesday after the company reported that it had received a license for ...
- Natco may seek compulsory licence for Bayer's cancer drugNatco Pharma plans to seek a compulsory licence to make Bayer AG's Nexavar in India, invoking a provision in local laws that allows generic...
- Bayer drags Cipla to court over patentGerman drugmaker Bayer has filed a patent infringement case against Cipla, the largest domestic drug seller, to stop the Mumbai-based compa...
- SC rejects Bayer’s plea to stay Cipla’s cancer cloneThe Supreme Court turned down a request by German drugmaker Bayer AG to stop Mumbai-based Cipla from launching the low-cost version of Baye...
- No interim stay on Cipla’s Nexavar cloneThe Supreme Court turned down a request by German drugmaker Bayer AG to stop Mumbai-based Cipla from launching the low-cost version of Baye...
- Bayer’s bid to stay Cipla cancer drug foiled, next hearing on Oct 6Germany's largest drug maker Bayer failed to get a court stay on Cipla from seeking permission to launch the European company’s copycat of ...
- Cipla's clone of Bayer cancer drug gets nodThis case was keenly watched by both pharma industry and health activists because it had much wider ramifications.
- Major win for Indian pharma cos as HC dismisses Bayer petitionThe Delhi High Court (HC) on Tuesday dismissed German drug major Bayer Healthcare’s attempt to stop Drug Controller General of India (DCGI)...
Load More- IPAB allows Natco Pharma to sell Nexavar; stock gains
